Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0000921895-19-002391
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-09-10 18:00:58
Reporting Period:
2019-09-06
Accepted Time:
2019-09-10 18:00:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1583648 Pieris Pharmaceuticals Inc. PIRS Investment Advice (6282) DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
918923 P L Fund Value Biotechnology 44 Montgomery Street
40Th Fl
San Francisco CA 94104
No No No Yes
1055947 P/il L Partners Bvf 44 Montgomery Street
40Th Fl
San Francisco CA 94104
No No Yes No
1056807 Bvf Inc/il 44 Montgomery Street
40Th Fl
San Francisco CA 94104
No No Yes No
1102444 Biotechnology Value Fund Ii Lp 44 Montgomery Street
40Th Fl
San Francisco CA 94104
No No No Yes
1233840 N Mark Lampert 44 Montgomery Street
40Th Fl
San Francisco CA 94104
No No Yes No
1660683 Biotechnology Value Trading Fund Os Lp P.o. Box 309 Ugland House
Grand Cayman E9 KY1-1104
No No No Yes
1660684 Ltd. Os Partners Bvf P.o. Box 309 Ugland House
Grand Cayman E9 KY1-1104
No No No Yes
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.001 Par Value Disposition 2019-09-06 23,152 $4.50 2,385,055 No 4 S Direct
Common Stock, $0.001 Par Value Disposition 2019-09-06 25,720 $4.50 2,233,074 No 4 S Direct
Common Stock, $0.001 Par Value Disposition 2019-09-06 1,128 $4.50 314,139 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock, $0.001 Par Value Series A Convertible Preferred Stock, $0.001 par value $0.00 1,567,000 1,567 Direct
Common Stock, $0.001 Par Value Series A Convertible Preferred Stock, $0.001 par value $0.00 1,021,000 1,021 Direct
Common Stock, $0.001 Par Value Series A Convertible Preferred Stock, $0.001 par value $0.00 319,000 319 Direct
Common Stock, $0.001 Par Value Series B Convertible Preferred Stock, $0.001 par value $0.00 2,573,000 2,573 Direct
Common Stock, $0.001 Par Value Series B Convertible Preferred Stock, $0.001 par value $0.00 2,143,000 2,143 Direct
Common Stock, $0.001 Par Value Series B Convertible Preferred Stock, $0.001 par value $0.00 284,000 284 Direct
Common Stock, $0.001 Par Value Tranche A Warrants $2.00 854,800 854,800 Direct
Common Stock, $0.001 Par Value Tranche A Warrants $2.00 560,400 560,400 Direct
Common Stock, $0.001 Par Value Tranche A Warrants $2.00 167,600 167,600 Direct
Common Stock, $0.001 Par Value Tranche B Warrants $3.00 427,400 427,400 Direct
Common Stock, $0.001 Par Value Tranche B Warrants $3.00 280,200 280,200 Direct
Common Stock, $0.001 Par Value Tranche B Warrants $3.00 83,800 83,800 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
1,567,000 1,567 Direct
1,021,000 1,021 Direct
319,000 319 Direct
2,573,000 2,573 Direct
2,143,000 2,143 Direct
284,000 284 Direct
854,800 854,800 Direct
560,400 560,400 Direct
167,600 167,600 Direct
427,400 427,400 Direct
280,200 280,200 Direct
83,800 83,800 Direct
Footnotes
  1. This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously owned in the aggregate more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
  2. Securities owned directly by BVF. As the general partner of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
  3. Securities owned directly by BVF2. As the general partner of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
  4. Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
  5. The Reporting Persons hold 2,907 shares of Series A Convertible Preferred Stock, (the "Series A Preferred Stock") convertible for an aggregate of 2,907,000 shares of Common Stock. Each share of Series A Preferred Stock is convertible into 1,000 shares of Common Stock. The Series A Preferred Stock is convertible at any time, at the holder's election, except that the Series A Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), more than 9.99% of the number of shares of Common Stock then issued and outstanding.
  6. The Reporting Persons hold 5,000 shares of Series B Convertible Preferred Stock, (the "Series B Preferred Stock") convertible for an aggregate of 5,000,000 shares of Common Stock. Each share of Series B Preferred Stock is convertible into 1,000 shares of Common Stock. The Series B Preferred Stock is convertible at any time, at the holder's election, except that the Series B Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock then issued and outstanding.
  7. The Reporting Persons hold 1,582,800 Tranche A Warrants (the "A Warrants") exercisable for an aggregate of 1,582,800 shares of Common Stock. The A Warrants have an exercise price of $2.00 per share and expire on June 8, 2021. The A Warrants are exercisable at any time, at the holder's election, except that the A Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock then issued and outstanding.
  8. The Reporting Persons hold 791,400 Tranche B Warrants (the "B Warrants") exercisable for an aggregate of 791,400 shares of Common Stock. The B Warrants have an exercise price of $3.00 per share and expire on June 8, 2021. The B Warrants are exercisable at any time, at the holder's election, except that the B Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock then issued and outstanding.